HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrile

Also Known As:
((18)F)FDDNP; (18F)FDDNP; 2-(1-(6-((2-((18)F)fluoroethyl)(methyl)amino)-2-naphthyl)ethylidene)malononitrile
Networked: 19 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Barrio, Jorge R: 9 articles (01/2013 - 01/2002)
2. Kepe, Vladimir: 8 articles (01/2013 - 01/2002)
3. Small, Gary W: 7 articles (01/2013 - 01/2002)
4. Huang, Sung-Cheng: 4 articles (01/2013 - 01/2002)
5. Satyamurthy, Nagichettiar: 4 articles (01/2013 - 01/2002)
6. van Berckel, Bart N M: 4 articles (06/2012 - 11/2008)
7. Tolboom, Nelleke: 4 articles (06/2012 - 11/2008)
8. Lammertsma, Adriaan A: 4 articles (06/2012 - 11/2008)
9. Siddarth, Prabha: 4 articles (02/2012 - 01/2002)
10. Scheltens, Philip: 3 articles (06/2012 - 02/2009)

Related Diseases

1. Alzheimer Disease (Alzheimer's Disease)
2. Amyloid Plaque
11/01/2008 - "[(18)F]FDDNP is a positron emission tomography (PET) tracer for determining amyloid plaques and neurofibrillary tangles in the brain in vivo. "
09/03/2003 - "FDDNP is a highly hydrophobic, viscosity-sensitive, solvent-sensitive, fluorescent substance, whose radiofluorinated analog [18F]FDDNP has recently been successfully used to label senile plaques and neurofibrillary tangles in the living brain of Alzheimer's disease patients with positron emission tomography. "
03/01/2007 - "A number of groups have worked to develop radiolabeled amyloid imaging agents, and clinical trials in AD patients have been reported with several agents including [18F]FDDNP, [11C]PIB, [11C]SB-13 and [123I]IMPY, indicating that detecting beta-amyloid plaques in the living human brain with amyloid imaging agents is potentially feasible. "
01/01/2002 - "The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. "
01/01/2003 - "We utilized in vitro competition assays, autoradiography, and fluorescence microscopy with AD brain specimens to demonstrate concentration-dependent decreases in the binding of the in vivo molecular imaging probe, 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile ([(18)F]FDDNP), against (S)-naproxen and (R)- and (S)-ibuprofen (but not diclofenac) to Abeta fibrils and ex vivo Abeta senile plaques. "
3. Down Syndrome (Down's Syndrome)
4. Neurodegenerative Diseases (Neurodegenerative Disease)
5. Disease Progression

Related Drugs and Biologics

1. Amyloid (Amyloid Fibrils)
2. N- methyl- 2- (4'- methylaminophenyl)- 6- hydroxybenzothiazole
3. 2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
4. 6- iodo- 2- (4'- dimethylamino- )phenyl- imidazo(1,2- a)pyridine
5. dicyanmethane (malononitrile)
6. Glucose (Dextrose)
7. Fluorine
8. Naproxen (Naprosyn)
9. Ibuprofen (Motrin)
10. Diclofenac (SR 38)